Hannah Harger Relapsed Wilms Tumor Trial
Enhancing Tumor-Associated Antigen Cytotoxic T-Cell Immunotherapy in Patients with Relapsed/Refractory Wilms Tumor
Children who relapse with Wilms tumors have a dismal prognosis and there are few targeted therapies or clinical trials available. Dr. Meany’s trial aims to fill this critical need with use of a therapy similar to the celebrated CAR-T therapy, which has not had thrilling results in solid tumors like it has in blood cancers. Dr. Meany’s protocol is a “first in human” approach to evaluate the targeting of multiple tumor associated antigens with T cells and combining it with chemotherapy in a novel way.
This Project By The Numbers
Years Active3 years
InstitutionChildren’s National Medical Center